Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Amortization - Intangibles (2021 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Amortization - Intangibles for 5 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortization - Intangibles changed 0.0% year-over-year to $2.7 million, compared with a TTM value of $10.8 million through Dec 2025, changed 0.0%, and an annual FY2025 reading of $10.8 million, changed 0.0% over the prior year.
  • Amortization - Intangibles was $2.7 million for Q4 2025 at Xeris Biopharma Holdings, roughly flat from $2.7 million in the prior quarter.
  • Across five years, Amortization - Intangibles topped out at $2.7 million in Q1 2022 and bottomed at $550000.0 in Q4 2021.
  • Average Amortization - Intangibles over 5 years is $2.6 million, with a median of $2.7 million recorded in 2022.
  • The sharpest move saw Amortization - Intangibles surged 392.91% in 2022, then dropped 0.04% in 2025.
  • Year by year, Amortization - Intangibles stood at $550000.0 in 2021, then surged by 392.91% to $2.7 million in 2022, then changed by 0.0% to $2.7 million in 2023, then changed by 0.0% to $2.7 million in 2024, then changed by 0.0% to $2.7 million in 2025.
  • Business Quant data shows Amortization - Intangibles for XERS at $2.7 million in Q4 2025, $2.7 million in Q3 2025, and $2.7 million in Q2 2025.